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Introduction: Acute normovolemic hemodilution (ANH) and volume loading (VL) are standard blood-sparing
procedures. However, VL is associated with hypervolemia, which may cause tissue edema, cardiopulmonary
complications and a prolonged hospital stay. The body reacts to hypervolemia with release of atrial natriuretic
peptide (ANP) from the heart. ANP has been shown to deteriorate the endothelial glycocalyx, a vital part of
the vascular permeability barrier. The aim of the present study was to evaluate and compare ANP release and
damage to the glycocalyx during ANH and VL.
Methods: ANH or VL with 6% hydroxyethyl starch 130/0.4 was administered prior to elective surgery in patients of
good cardiopulmonary health (n =9 in each group). We measured concentrations of ANP in plasma and of three main
constituent parts of the glycocalyx (hyaluronan, heparan sulfate and syndecan 1) in serum before and after ANH or VL.
Heparan sulfate and syndecan 1 levels in urine were also determined.
Results: In contrast to ANH, VL (20 ml/kg) induced a significant release of ANP (approximately +100%, P <0.05) and
increased the serum concentration of two glycocalyx constituents, hyaluronan and syndecan 1 (both by about 80%,
P <0.05). Elevation of syndecan 1 was also detected in the urine of patients undergoing VL, but no increase was found
in patients undergoing ANH. Heparan sulfate levels were not influenced by either procedure.
Conclusion: These data suggest that hypervolemia increases the release of ANP and causes enhanced shedding of the
endothelial glycocalyx. This perturbation must be expected to impair the vascular barrier, implying that VL may not be
as safe as generally assumed and that it should be critically evaluated.Introduction
On the surface of healthy vascular endothelium resides a
structure, the endothelial glycocalyx, that consists of
extracellular domains of receptor, adhesion and channel
proteins and, foremost, of molecules such as trans-
membrane syndecan 1 (bearing covalently bound, highly
negatively charged glycosaminoglycans, such as heparan
and chondroitin sulfates) and the receptor-bound, long-
chained hyaluronic acid molecule [1,2]. Together with
bound plasma proteins and glycosaminoglycans, the gly-
cocalyx forms the endothelial surface layer with a func-
tional thickness of more than 1 μm [3,4]. Disruption
of the glycocalyx has been shown to increase capillary* Correspondence: dirk.bruegger@med.uni-muenchen.de
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unless otherwise stated.permeability and firm attachment of leukocytes and blood
platelets, leading to tissue edema, suggesting that the gly-
cocalyx acts as a competent permeability barrier and anti-
adhesive interface with blood [5]. In patients in septic
shock, glycocalyx shedding has been found to be associ-
ated with increased mortality and to be an independent
predictor of mortality in trauma patients [6-8].
Traditional perioperative fluid therapy is often per-
formed in a liberal manner, leading to fluid overload and
tissue edema. In clinical studies, hypervolemia has been
shown to have detrimental influences on several aspects
of patient outcome, including cardiopulmonary complica-
tions, anastomotic insufficiency, length of hospital stay,
duration of mechanical ventilation and mortality [9-11].
One possible underlying trigger may be the release of
atrial natriuretic peptide (ANP) from the cardiac atria in-
voked by mechanical wall stress [12]. ANP is known to in-
duce rapid shifts of intravascular fluid into the interstitialal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Chappell et al. Critical Care 2014, 18:538 Page 2 of 8
http://ccforum.com/content/18/5/538space and has been shown to cause deterioration of
the endothelial glycocalyx. In an isolated heart model,
artificially infused ANP induced an increase in vascular
permeability, a histologically detectable degradation of the
glycocalyx and significant tissue edema [13]. Furthermore,
an increase in plasma ANP has been found to precede
shedding of the glycocalyx in patients undergoing coronary
bypass surgery [14].
ANP is released during hypervolemia, which could ex-
plain the context sensitivity of volume effects of iso-
oncotic colloidal infusions (for example, 6% hydroxyethyl
starch or 5% human albumin) [15,16]. The “volume effect”
is that part of an infused fluid bolus that remains within
the vasculature for a longer period. Direct blood volume
measurements have revealed that the presumed volume
effect of about 100% for such colloids is realized only in
normovolemic patients—that is, during acute normovole-
mic hemodilution (ANH), a procedure in which blood is
withdrawn and simultaneously replaced by equal amounts
of colloidal fluid [16]. During volume loading (VL) (that
is, the hypervolemic infusion of colloids into a primarily
normovolemic circulation without simultaneous blood
withdrawal), about 60% of the infused amount was
observed to directly load the interstitial space within
30 minutes, leaving a volume effect of merely 40% [15].
Also, 60% of the infused fluid was found to leave the intra-
vascular space, and 60% of the administered macro-
molecules (hydroxyethyl starch (HES) and albumin) were
extravasated.
The aim of the present study was to investigate com-
paratively whether the established blood-sparing proce-
dures VL (hypervolemia) and ANH (normovolemia) are
associated with increased ANP levels and shedding of
the endothelial glycocalyx.
Material and methods
The study was approved by the independent ethics
committee of our institution (Medical Faculty of the
Ludwig-Maximilians-University Munich, Germany; trial regis-
tration 128-04), and all patients included gave us their written
informed consent to participate. Inclusion criteria were
patient consent, good cardiopulmonary health, expected
blood loss of more than 500 ml, and preoperative indica-
tion of the necessity to insert arterial and central venous
catheters. The study was performed before the results of
the 6S and CHEST trials were published (Scandinavian
Starch for Severe Sepsis/Septic Shock trial and Crystalloid
versus Hydroxyethyl Starch trial, respectively) [17,18].
Anesthesiological procedure
The mandatory fasting period after consumption of solid
food, milk and milk-containing fluids was 6 hours, and
clear fluids were allowed up to 2 hours before induction
of anesthesia. After each patient arrived in the operatingtheatre, monitoring with electrocardiography and pulse
oximetry was implemented. General anesthesia was in-
duced with 0.5 μg/kg sufentanil, 2 mg/kg propofol and
0.1 mg/kg cisatracurium, and, after tracheal intubation,
anesthesia was maintained with 1.6% to 2.0% sevoflurane.
Radial artery and central venous catheters were inserted.
Mechanical ventilation was performed to maintain partial
pressure of arterial oxygen at 100 to 150 mmHg and par-
tial pressure of carbon dioxide at 40 ± 5 mmHg. No intra-
venous infusions were applied, except for negligible
amounts required to inject the intravenous drugs. After a
steady state was achieved, the patients were assigned to re-
ceive either VL or ANH.
Acute normovolemic hemodilution
Blood was removed at a rate of about 60 ml/min via the ar-
terial line and simultaneously replaced with iso-oncotic
HES colloid solution (6% HES 130/0.4 (Volulyte); Fresenius
Kabi, Bad Homburg, Germany) at almost the same rate
through the central venous line. At first, a quantity of
approximately 500 ml/m2 of blood was removed. The
hemodilution bags were weighed on a precision scale
so that the volume of withdrawn blood could be evaluated
immediately. For fine-tuning, frequent determinations of
hematocrit were carried out to reach a target hematocrit
level of 24 ± 2%. The hemodilution procedure took about
30 minutes.
Volume loading
VL was initiated by infusing 20 ml/kg of an iso-oncotic
HES colloid solution (6% HES 130/0.4, Volulyte) within
15 minutes at a rate of approximately 90 ml/min.
Blood sampling
In all patients, blood and urine samples were taken dir-
ectly after induction of anesthesia (pre) to determine basal
values. Both VL and ANH procedures were initiated im-
mediately thereafter and lasted for 30 minutes, followed
by the second blood and urine sampling (post). The time
window for the present study was chosen because we
knew from previous direct double-tracer blood volume
measurements that, after VL with 5% human albumin or
6% HES administration, the total volume of the endothe-
lial surface layer (glycocalyx and bound plasma proteins)
would be significantly reduced 30 minutes after the
procedure [15]. The patients were kept strictly in supine
position during the whole investigation period. All mea-
surements were performed before surgical incisions were
made.
Determination of glycocalyx constituents
Immediately after withdrawal into serum vials, blood
samples were centrifuged at 2,000 g for 10 minutes. The
serum fraction was frozen and stored at −80°C until
Table 1 Patient characteristicsa
VL ANH
Age (yr) 57 ± 4 55 ± 2
Height (cm) 170 ± 2 166 ± 2
Weight (kg) 67 ± 3 64 ± 4
BSA (m2) 1.8 ± 0.1 1.7 ± 0.1
Blood removed (ml) 1,267 ± 62
Colloid infused (ml) 1,326 ± 50 1,298 ± 71
Urine production (ml) 213 ± 66 228 ± 29
Baseline serum albumin (g/dl) 4.1 ± 0.1 4.1 ± 0.1
aValues are given as mean ± SEM. There were no significant differences
between the VL and ANH groups with respect to applicable parameters. Urine
production was determined 30 minutes after fluid infusion (VL) or 30 minutes
after blood draw (ANH), respectively. ANH, Acute normovolemic hemodilution;
BSA, Body surface area; VL, Volume loading.
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assayed.
Syndecan 1 concentration
Syndecan 1 concentrations in serum and urine were deter-
mined directly as previously reported by using an enzyme-
linked immunosorbent assay kit (Diaclone Research,
Besancon, France) [14,19,20]. In this kit, a solid-phase
monoclonal B-B4 antibody against an extracellular do-
main of syndecan 1 is employed.
Heparan sulfate concentration
Serum and urinary heparan sulfate concentrations were
quantified using a special enzyme-linked immunosorbent
assay kit (Seikagaku, Tokyo, Japan) as previously reported
[14,19,21-23]. Serum was pretreated with protease from
Streptomyces griseus (Actinase E; Sigma-Aldrich, St Louis,
MO, USA). This kit employs two monoclonal antibodies
specific for heparan sulfate–related epitopes.
Hyaluronan concentration
Hyaluronan concentrations were measured in serum using
an enzyme-linked immunosorbent assay kit (Echelon
Biosciences, Salt Lake City, UT, USA) designed to detect
human hyaluronic acid, as previously described [14,23].
Hyaluronan concentrations were not measured in urine,
because renal excretion plays a negligible part in clearance.
The major part of the elimination of hyaluronan (about
90%) from the systemic circulation occurs in the liver
via receptor-mediated endocytosis in the sinusoidal liver
endothelial cells [24,25].
Atrial natriuretic peptide concentration
Blood was sampled into ethylenediaminetetraacetic acid in
vials and centrifuged immediately (2,000 g, 10 minutes).
The plasma was directly frozen and stored at −80°C until
assayed. Plasma levels of ANP were measured with a
sandwich enzyme-linked immunosorbent assay kit (Uscn
Life Science, Wuhan, China) with an antibody specific to
human ANP as performed previously [14]. The kit did not
require a preliminary step for extraction or purification of
plasma samples.
Statistical analysis
A preliminary sample size calculation was based on a
previous study in which researchers investigated ANP
concentrations after VL with 500 ml of 6% HES and
1,000 ml of Ringer’s lactate solution in patients before
caesarean section [26]. The difference between mean
ANP before and after VL was 17.9 pg/ml. Using this dif-
ference and the corresponding standard deviations, we
calculated a sample size with a two-sided confidence inter-
val of 0.95 and a desired power of 0.80, which yielded a re-
sult that we needed nine patients in each group. Data aregiven as mean ± SEM. All data were compared by per-
forming Student’s t-test, with P <0.05 considered sta-
tistically significant (SigmaStat; Systat Software, Richmond,
VA, USA).
Results
Demographic data and procedural characteristics
All patients were attested to be in good cardiopulmonary
health and were scheduled for elective general surgery
with an expected blood loss greater than 500 ml. As the
measuring time points were all before skin incision, the
individual diagnosis and operation had no influence on
the study. The pertinent patient characteristics and ini-
tial albumin concentrations are listed in Table 1. Patients
in the VL group received 1,326 ± 50 ml of 6% HES solu-
tion after induction of anesthesia. In the ANH group,
1,267 ± 62 ml of blood were drawn and simultaneously
replaced with similar amounts of 6% HES 130/0.4. Not-
ably, urine production was not increased in the VL
group compared to the ANH group during the first 30-
minute period of the intervention.
Atrial natriuretic peptide
All data are normalized to grams per deciliter of plasma
albumin to account for varying degrees of hemodilution
in individual patients. Basal ANP concentrations in plasma
showed no difference between the VL and ANH groups
(13.6 ± 6.2 ng/g vs. 13.4 ± 3.5 ng/g albumin). Thirty mi-
nutes after the procedures, ANP concentrations had
increased in the VL group to 25.1 ± 11.4 ng/g albu-
min, whereas the ANP concentration in the ANH group
remained almost unchanged at 14.8 ± 5.6 ng/g albumin
(P <0.05) (Figure 1).
Shedding of components of the endothelial glycocalyx
To account for hemodilution, individual heparan sulfate,
hyaluronan and syndecan 1 concentrations were normal-
ized to the individual albumin concentrations. Respective
Figure 1 Atrial natriuretic peptide concentrations. Atrial natriuretic peptide concentrations before (pre) and after (post) volume loading
(VL, n =9) or acute normovolemic hemodilution (ANH, n =9) with 6% hydroxyethyl starch 130/0.4. To account for hemodilution, individual
atrial natriuretic peptide concentrations were normalized to the individual albumin concentrations. Data are given as mean ± SEM. *P <0.05
(significantly different from pre).
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can 1 concentrations did not differ between the groups
(heparan sulfate: 2.8 ± 0.7 μg/g albumin vs. 2.6 ± 0.6 μg/g
albumin; hyaluronan: 32.6 ± 5.5 μg/g albumin vs. 32.7 ±
3.7 μg/g albumin; syndecan 1: 24.8 ± 8.1 vs. 30.1 ± 8.4 μg/g
albumin) (Figure 2). Figure 2 illustrates the changes in the
concentrations of the three glycocalyx constituents in both
groups. Serum heparan sulfate concentrations remained
almost unchanged after both VL and ANH (Figure 2a).
Interestingly, the serum hyaluronan concentration in-
creased significantly to 56.4 ± 12.2 μg/g albumin in the VL
group 30 minutes after the procedure, whereas the level
remained unchanged in the ANH group (Figure 2b). Also,
a significant increase in serum syndecan 1 concentration
to 45.4 ± 14.9 μg/g albumin was found in the VL group
30 minutes after VL. Again, no change in serum syndecan
1 was seen 30 minutes after ANH (Figure 2c).
Renal excretion of components of the endothelial
glycocalyx
Figure 3 shows the changes in urinary concentrations of
two glycocalyx components known to pass through the
glomerular barrier. Urinary heparan sulfate concentra-
tions remained unchanged both after VL and after ANH
(Figure 3a). In contrast, urinary syndecan 1 concentra-
tions increased significantly in the VL group 30 minutesafter VL (P <0.05). No such increase was found in the
ANH group (Figure 3b).
Discussion
The results of the present study reveal that hypervolemia
induced by VL is associated with increased plasma con-
centrations of ANP and raised serum levels of two main
constituents of the endothelial glycocalyx. ANH had no
comparable effects.
ANH and VL are well-established, frequently used
blood-sparing procedures. The main goal of ANH is to
withdraw whole blood, which is stored outside the body,
and replace this volume with iso-oncotic colloids, thereby
diluting the remaining blood whilst retaining a constant
normovolemic blood volume [27]. In this situation, iso-
oncotic colloids have a volume effect of nearly 100%,
meaning that the entire infused volume remains in the cir-
culation [16]. In the event of subsequent bleeding, there is
a loss of diluted, hemoglobin-reduced blood, which can be
replaced with the previously withdrawn hemoglobin-rich
blood when the individual transfusion cutoff value is
reached. VL, in contrast, dilutes the blood by expanding
the blood volume [27]. In previous studies, direct blood
volume measurements have revealed that, during the VL
procedure, only 40% of the infused colloids remain within
the vasculature [15]. The other 60% are shifted to the
Figure 2 Serum concentrations of glycocalyx components.
Serum concentrations of heparan sulfate (a), hyaluronan (b) and
syndecan 1 (c) before (pre) and after (post) volume loading (VL,
n = 9) or acute normovolemic hemodilution (ANH, n = 9) with
6% hydroxyethyl starch 130/0.4. To account for hemodilution,
individual heparan sulfate, hyaluronan and syndecan 1 concentrations
were normalized to the individual albumin concentrations. Data are
given as mean ± SEM. *P <0.05 (significantly different from pre).
Figure 3 Urinary concentrations of glycocalyx components.
Urinary concentrations of heparan sulfate (a) and syndecan 1 (b)
before (pre) and after (post) volume loading (VL, n = 9) or acute
normovolemic hemodilution (ANH, n = 9) with 6% hydroxyethyl
starch 130/0.4. Data are given as mean ± SEM. *P <0.05 (significantly
different from pre).
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behind this colloid shifting seems to be an impaired glyco-
calyx structure, as evidenced by a considerable decrease in
the total volume of the endothelial surface layer [15]. The
results of the present study offer an explanation for this
phenomenon: ANP is released from human atria during
iatrogenic hypervolemia, inducing shedding of constituent
parts of the endothelial glycocalyx.
ANP has well-known diuretic, natriuretic and vasodilat-
ing effects. Furthermore, this polypeptide hormone also
induces rapid shifts of intravascular fluid into the intersti-
tial space [12,28]. Experimental and clinical studies have
revealed that elevation of ANP is associated with increased
shedding of the endothelial glycocalyx [13,14].
A possible connection between the ability of ANP to
acutely shift volume from the intra- to extravascular
spaces and its influence on the integrity of the endothe-
lial glycocalyx has been investigated in an experimental
setting by our group [13]. Infusion of ANP in an isolated
heart model caused an increase in fluid leak and an ac-
celerated extravasation of colloid. Furthermore, ANP re-
sulted in rapid shedding of the endothelial glycocalyx
and histologically detectable destruction of the coronary
vascular glycocalyx [13]. Accordingly, the ANP-induced
increase in vascular permeability described in vivo might
be related to changes in the integrity of the glycocalyx.
This fragile structure is a crucial part of the vascular bar-
rier, and its deterioration has been shown to cause shift-
ing of fluids and colloids into the interstitial space with
concomitant tissue edema.
Indirect evidence for such an effect comes from a re-
cent study of patients undergoing coronary artery bypass
surgery [14]. Three major components of the endothelial
glycocalyx were shed from the endothelium and detected
in the circulating blood of patients during both on- and
off-pump coronary artery bypass surgeries. Comparison
of the respective time courses of glycocalyx shedding
with release of ANP and various cytokines designated
ANP as the mediator that most likely initiated shedding
in both surgical procedures [14].
Perioperative fluid therapy is currently being discussed
intensively concerning not only the kind of fluid but also
the right amount. A further aspect of debate is when to
infuse the fluid. The danger of hypovolemia’s causing
organ hypoperfusion and increasing the risk of systemic
inflammation has been known for decades. However,
awareness that hypervolemia can have similar detrimen-
tal effects on patient outcomes is relatively new. Fluid
overload has been shown to abet anastomotic leakage,
pulmonary edema, pneumonia and wound infection, as
well as postoperative ileus [10,11,29]. Individually, both
the surgical impact (inflammation, trauma) and the trad-
itional liberal fluid strategy have the potential to impair
the competence of the vascular barrier. The combinationof both confounders increases this effect significantly. A
breakdown of vascular barrier competence results in capil-
lary leakage and protein-rich interstitial edema, which lead
to a significant perioperative increase in body weight. In
clinical trials, this has been shown to be associated with
increased morbidity and mortality [9-11]. The data derived
from the present study support the need for a rational
fluid management strategy to maintain normovolemia by
replacing actual losses in an adequate manner and avoid
unnecessary fluid boluses.
HES preparations are frequently used in clinical prac-
tice because their intravascular volume effect is high and
their deposition in tissue is low. Under pathological con-
ditions, however, this might not inevitably be the case.
Patients with severe sepsis and in septic shock, for ex-
ample, need very large amounts of fluid to stabilize cardiac
preload. Trials have revealed a significantly decreased vol-
ume effect of colloids in this situation, despite remaining
superior to crystalloids [30-33]. This effect not only is as-
sociated with severe tissue edema but also can cause ser-
ious side effects that have a negative impact on patient
outcome. Experimental data support the observation that
colloids may be retained insufficiently at the vascular
barrier during capillary leakage [34]. Our experimental
findings are in agreement with these clinical observations
linking degradation of the glycocalyx to colloid and fluid
extravasation.
One key question is whether the renal or the vascular
effects of ANP stand in the foreground. In our study, we
measured no difference in urinary output between these
groups, although patients in the VL group were subjected
to hypervolemia. However, our urine-sampling period ter-
minated directly after fluid infusion and thus was probably
too short to detect changes in urinary output. Indeed,
Drummer et al. demonstrated that an intravenous volume
bolus of 2 L in healthy volunteers required more than
48 hours to be completely excreted [35]. Nevertheless, the
unchanged urine production in our study allowed us to
analyze clearly the results obtained for urinary elimination
of heparan sulfate and syndecan 1. The urinary concentra-
tion of the former did not differ between pre- and postin-
tervention for either the VL or ANH patients, whereas the
syndecan 1 concentration increased in the VL group.
Thus, urinary elimination directly reflects the alteration in
blood level determined for these two glycocalyx constitu-
ents, with no masking or simulation of shedding on the
basis of renal clearance.
One limitation of this trial is that biomarkers of glyco-
calyx shedding are only an indirect method of measuring
glycocalyx thickness and integrity and do not provide
insight into the thickness of the remaining glycocalyx
structure. Furthermore, we used a third-generation bal-
anced 6% hydroxyethyl starch 130/0.4 solution, so, despite
volume effects similar to those seen with other iso-oncotic
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this trial are not directly transferable to other colloids.
Surprisingly, we found only two markers of glycocalyx
degradation to be elevated in the serum of the VL group:
syndecan 1 and hyaluronan. It should be borne in mind
that shedding of these two constituents requires the ac-
tion of proteases, whereas the lyase heparanase is needed
for shedding of heparan sulfates in humans. Accordingly,
VL cannot lead to any marked activation or release of
heparanase in humans. A major store of heparanase in
humans is in the tissue mast cells [36]. Fittingly, there
are no receptors for ANP on the human mast cell. Thus,
VL-induced liberation of ANP is a realistic mechanism
by which to explain our finding of dissociated markers
of glycocalyx damage.
Conclusion
The results of our trial show that the transfusion-sparing
procedure of VL may not be as safe as believed. Hypervo-
lemia has detrimental effects on vascular barrier compe-
tence and may impair patient outcome. We recommend
abstaining from preoperative volume boluses and favoring
ANH should hemodilution be warranted to reduce peri-
operative red cell transfusion. Future research in general is
warranted in the area of fluid administration that takes
the glycocalyx into consideration and includes deducing
optimal volume amounts and rates of infusion that will
maintain intravascular volume without causing disruption
of the endothelial glycocalyx.
Key messages
 ANP is released during preoperative VL.
 VL causes increased shedding of the endothelial
glycocalyx.
 Glycocalyx components can be detected in both
serum and urine 30 minutes after VL.
 ANH has much lower effects on both glycocalyx
shedding and ANP release, respectively.
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